Iroko Pharmaceuticals LLC is categorized under in Philadelphia, PA and active since 2007.
Iroko Pharmaceuticals LLC was established in 2007, and today employs 1 to 4, earning $50.000.000 to $99.999.999 per year. This is a business, which does work in the B2B market, and is classified as a , under code number 4242101 by the NAICS.
If you are seeking more information, feel free to contact John Vavricka, Chief Executive Officer at the company’s single location by writing to 150 Rouse Boulevard, Philadelphia, Pennsylvania PA 19112 or by phoning (267) 546-3003. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Iroko Pharmaceuticals LLC |
| Contact Person: | John Vavricka, Chief Executive Officer |
| Address: | 150 Rouse Boulevard, Philadelphia, Pennsylvania 19112 |
| Phone Number: | (267) 546-3003 |
| Website Address: | iroko.com |
| Annual Revenue (USD): | $50.000.000 to $99.999.999 |
| Founded: | 2007 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | |
| SIC Code: | 2834 |
| NAICS Code: | 4242101 |
| Share This Business: |
Iroko Pharmaceuticals LLC was started in 2007 to provide professional under the SIC code 2834 and NAICS code 4242101. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000.000 to $99.999.999 per annum.
Feel free to contact John Vavricka, Chief Executive Officer for inquiries that concern Iroko Pharmaceuticals LLC by calling the company number (267) 546-3003, as your correspondence is most welcome. Additionally, the physical location of the single location of Iroko Pharmaceuticals LLC can be found at the coordinates 39.8918,-75.172 as well as the street address 150 Rouse Boulevard in Philadelphia, Pennsylvania 19112.
For its online presence, you may visit Iroko Pharmaceuticals LLC’s website at iroko.com and engage with its social media outlets through on Twitter and on Facebook.